Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Program Overview

This activity has been designed to meet the educational needs of healthcare providers involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Credit Expired

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians attending the virtual IASLC 2021 World Conference on Lung Cancer meeting and who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze the predictive/prognostic significance of EGFR exon 20 insertion
mutations in non-small cell lung cancer (NSCLC)
Apply optimal diagnostic strategies for identifying NSCLC with EGFR
exon 20 insertions
Assess clinical trial data regarding new and emerging treatment options
for advanced NSCLC with EGFR exon 20 insertions
Employ appropriate techniques to manage adverse events associated
with EGFR inhibition

Activity Faculty

Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI

Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy

Featured RMEI CE Activities – Earn CE Credit(s)

Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)

Shirish M. Gadgeel, MD

Antonio Passaro, MD, PhD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe